ArticleBMC urology2025
Urethral hemangioma with carcinoma in situ: a case report.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multicenter retrospective study of 108 men with urethral hemangioma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrethral hemangioma is an exceptionally rare benign vascular tumor, with scarce data available on its natural history and therapeutic strategies. The coexistence of carcinoma in situ within urethral hemangioma has not been previously documented in medical literature. CASE PRESENTATION: A 62-year-old woman presented with a protruding mass at the external urethral orifice. The lesion was completely excised by surgical resection. Histopathological analysis revealed squamous cell carcinoma in situ (SC-CIS) within the urethral hemangioma. The patient refused to undergo repeat surgical treatment again for SC-CIS due to surgical complications. The patient received adjuvant radiotherapy (total dose 50 Gy/25 fractions) following pathological confirmation of involved surgical margins. Long-term follow-up, including annual CT scans and cystoscopies, showed no evidence of disease recurrence at 7 years post-treatment.
conclusionFew cases of urethral hemangioma have been documented in the literature, and no previous reports have descried urethral hemangiomas coexisting with SC-CIS. Surgical treatment emphasizes the complete resection of the lesions. When margin involvement by malignant cells was identified, adjuvant radiotherapy is an essential component of the combined-modality approach. The 7-year recurrence-free survival in this case suggests that this combined-modality approach provides durable local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.